ERBB3 and head and neck squamous cell carcinoma: Collectively, this supports that PI3K-AKT–mTOR may represent a key target downstream from HER3, and that CDX-3379 exerts therapeutic effects primarily in PIK3CA wild type HNSCC xenografts.